Results 81 to 90 of about 34,994 (236)

Germline Cancer Predisposition and De Novo Contributions in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group

International Journal of Cancer, EarlyView.
ABSTRACT Approximately 6%–8% of children and adolescents with rhabdomyosarcoma (RMS) have an underlying cancer predisposition disorder (CPD), which varies between embryonal and alveolar subtypes and other clinical characteristics. Identifying a CPD remains challenging, as traditional approaches rely on clinical features and family history. Additionally,
Taylor M. Luckie, Sarah Scollon, Yao Yu, Aniko Sabo, Tiffany Chambers, Olga Taylor, Logan G. Spector, Michael E. Scheurer, Douglas S. Hawkins, Rajkumar Venkatramani, Chad D. Huff, Sharon E. Plon, Philip J. Lupo   +12 more
wiley   +1 more source

Impact of Molecular Alterations on Survival in Biliary Tract Cancers: A Retrospective Belgian Cohort Study

International Journal of Cancer, EarlyView.
ABSTRACT Biliary tract cancers (BTCs) are aggressive malignancies associated with a poor prognosis. Although molecular profiling is recommended to guide therapeutic decision‐making, real‐practice data on the prevalence and prognostic significance of genomic alterations in European BTC cohorts remain limited.
Jorine Arnouts, Léon C. van Kempen, Senada Koljenović, Helena Oliveres, Pieterjan Vanclooster, Hans Prenen, Caro De Weerdt, Siddharth Chhajlani, Geert Roeyen, Laure Sorber, Koen De Winne, Jonas Dahnoun, Greetje Vanhoutte, Timon Vandamme, Karen Zwaenepoel   +14 more
wiley   +1 more source

Leveraging Healthy Volunteers for Anticancer Drug Clinical Pharmacology Studies: A Review Article Featuring Futibatinib as an Example. [PDF]

Clin Transl Sci
ABSTRACT Early clinical development of anticancer drugs traditionally focused on exploring candidate treatments in patients. For instance, due to their cytotoxic action, administration of chemotherapies to healthy volunteers (HVs) for evaluation of their pharmacokinetic profiles was not considered feasible nor ethical from a safety and tolerability ...
van Haarst AD, Paglialunga S, Machnes Z, Yamamiya I, Hangai N, Oganesian A.   +5 more
europepmc   +2 more sources

Association of FGF-2, FGFR-2 and FGFR-3 with clinico-pathological features in OSCC.

, 2015
Association of FGF-2, FGFR-2 and FGFR-3 with clinico-pathological features in OSCC.
Vikram Bhatia (406012), Seema Nayak (813016), Annu Makker (813017), Saumya Chandra (813018), Sandeep Kumar (145759), Madhu Mati Goel (473426), S. P. Agarwal (813019)   +6 more
core   +1 more source

Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer

International Journal of Cancer, EarlyView.
ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue, Daniele Carchidi, Philipp Schmucker, Roland Seiler, Bernhard Kiss, Catarina Macedo‐Silva, Marianna Kruithof‐de Julio   +6 more
wiley   +1 more source

Relation of FGF-2, FGFR-2 and FGFR-3 expression with clinico-pathological parameters in PMOLs.

, 2015
Relation of FGF-2, FGFR-2 and FGFR-3 expression with clinico-pathological parameters in PMOLs.
Vikram Bhatia (406012), Seema Nayak (813016), Annu Makker (813017), Saumya Chandra (813018), Sandeep Kumar (145759), Madhu Mati Goel (473426), S. P. Agarwal (813019)   +6 more
core   +1 more source

Lineage-specific biomarkers predict response to FGFR inhibition [PDF]

, 2012
In this issue of Cancer Discovery, Guagnano and colleagues use a large and diverse annotated collection of cancer cell lines, the Cancer Cell Line Encyclopedia, to correlate whole-genome expression and genomic alteration datasets with cell line ...
Pollock, Pamela M., Loch, David
core   +1 more source

Human biomarker navigator

iMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li, Qian Zhang, Zijie Wang, Zeping Gui, Jing Liu, Jingda Li, Maojun Jiang, Zukang Chang, Qingqing Han, Bendong Yang, Tariq Saeed, Jun Li, Jinghan Jia, Chenghu Song, Tong Shao, Tianhuan Peng, Xueying Zhang, Pingping Guo, Jun Luo, Gangao Yang, Yuan Wan, Gokhan Zengin, Quan Yuan, Lingru Li, Xiaohui Fan, Yang Luo, Lvyun Zhu, Yanfei Zheng, Wenjun Mao, Wenlong Sun   +29 more
wiley   +1 more source

FGFR2-fusions define a clinically actionable molecular subset of pancreatic cancer

npj Precision Oncology
Genomic alterations in fibroblast growth factor receptor (FGFR) genes are present in a small number of metastatic pancreatic ductal adenocarcinomas (PDAC) and may represent an emerging subgroup of patients likely to benefit from FGFR targeted therapies ...
Leah Stein, Karthikeyan Murugesan, Julie W. Reeser, Zachary Risch, Michele R. Wing, Anoosha Paruchuri, Eric Samorodnitsky, Emily L. Hoskins, Thuy Dao, Amy Smith, Dat Le, Melissa A. Babcook, Yi Seok Chang, Matthew R. Avenarius, Muhammad Imam, Aharon G. Freud, Sameek Roychowdhury   +16 more
doaj   +1 more source

The regulation of stem cell fate and its application in neural regeneration

Interdisciplinary Medicine, EarlyView.
Regulating stem cell fate is crucial for neural regeneration. This review summarizes key physical, biological, and chemical strategies and their applications in repairing nerve injuries, providing new insights for regenerative medicine. Abstract Regulating the fate of stem cells (SCs) is a key technical problem in the field of regenerative medicine and
Yuexin He, Xingyu Chen, Minghong He, Zhe Li   +3 more
wiley   +1 more source